Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant DDI with Midazolam in Healthy Females
NCT06256510Phase 1Completed
- Sponsor
- Pfizer
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vepdegestrant in breast cancer, sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration of Midazolam and Area Under the Curve From Time Zero to Extrapolated Infinite Time of Midazolam. Started Feb 2024; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06256510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06256510.